Sign in →

Test Code PDETS Phosphodiesterase 10A (PDE10A) IgG, Tissue Immunofluorescence Titer, Serum


Specimen Required


Only orderable as a reflex. For more information see:

ENS2 / Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Serum

DMS2 / Dementia, Autoimmune/Paraneoplastic Evaluation, Serum

EPS2 / Epilepsy, Autoimmune/Paraneoplastic Evaluation, Serum

MDS2 / Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Serum


Useful For

Reporting an end titer result from phosphodiesterase 10A (PDE10A) in serum specimens

 

Evaluation of autoimmune/paraneoplastic neurological syndromes among patients presenting with movement disorders and encephalopathy

Method Name

Only orderable as a reflex. For more information see:

ENS2 / Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Serum

DMS2 / Dementia, Autoimmune/Paraneoplastic Evaluation, Serum

EPS2 / Epilepsy, Autoimmune/Paraneoplastic Evaluation, Serum

MDS2 / Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Serum

 

Indirect Immunofluorescence Assay (IFA)

Reporting Name

PDE10A Ab IFA Titer, S

Specimen Type

Serum

Specimen Stability Information

Specimen Type Temperature Time
Serum Refrigerated (preferred) 28 days
  Frozen  28 days
  Ambient  72 hours

Reject Due To

Gross hemolysis Reject
Thawing** Cold OK; Warm OK
Gross lipemia Reject
Gross icterus Reject

Clinical Information

Phosphodiesterase 10A (PDE10A) is a marker of paraneoplastic neurological autoimmunity in patients presenting with movement disorders, encephalopathy and often cancer.

Reference Values

Only orderable as a reflex. For more information see:

ENS2 / Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Serum

DMS2 / Dementia, Autoimmune/Paraneoplastic Evaluation, Serum

EPS2 / Epilepsy, Autoimmune/Paraneoplastic Evaluation, Serum

MDS2 / Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Serum

 

<1:240

Day(s) Performed

Monday through Sunday

Report Available

5 to 10 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

86256